Search the Newsreel

Weave Communications (NYSE:WEAV) Upgraded by Wall Street Zen to Buy Rating

Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Wave Life Sciences Ltd. (WVE), highlighting weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies, including long, breakout, and short positions, with specific entry zones, targets, and stop …

CRWV Stock Rallies 13% After-Hours — AI Compute Demand Has Pushed CoreWeave Revenue To More Than Double

Haverty Furniture Companies (NYSE:HVT) Upgraded at Wall Street Zen

Aveanna Healthcare (NASDAQ:AVAH) Stock Rating Lowered by Wall Street Zen

Aveanna Healthcare (AVAH) Stock Climbs On Higher Guidance And Cash Flow

CRWV Stock Gains Premarket Amid Market Rebound: Neocloud Operator Announces $3.5B Debt Raise

Wave Life Sciences, Inc.: Revenue and Earnings Analysts Forecasts Revisions | WVE | US94352A1043

Nasdaq, S&P 500 Futures Fall Ahead Of CPI Data, Oracle Earnings: Why SMCI, TSM, CRWV, YYGH Are Keeping Traders Engaged Today

QBTS Stock Gets A Thumbs Down From Investors After 81% Revenue Decline – But Bookings Soar By A Whopping 1994%

Magnetar funds trim CoreWeave (CRWV) position with 1.92M-share sale

Magnetar-affiliated entities have reduced their indirect stake in CoreWeave, Inc. (CRWV) by selling 1,921,259 shares of Class A Common Stock across 27 transactions on August 13, 2026. The sales occurred at various prices, including weighted averages, with a total value of approximately $213.78 million. …

CoreWeave (CRWV) Magnetar-managed funds sell 307,131 Class A shares in August trades

Entities associated with Magnetar Financial LLC, including Magnetar Capital Partners LP and Supernova Management LLC, reported the sale of 307,131 shares of CoreWeave (CRWV) Class A Common Stock on August 14, 2026. These sales were executed across 24 non-derivative transactions by various Magnetar-managed funds, …

Magnetar entities (CRWV) report sale of 200,000 CoreWeave-linked warrants

Magnetar Financial LLC and related entities, a 10% owner of CoreWeave, Inc. (CRWV), reported the sale of 200,000 warrants linked to CoreWeave Class A common stock on August 14, 2026. These warrants were sold at $106.7505 per underlying share, with an exercise price of …

CoreWeave (CRWV) 10% owner Magnetar Financial sells $213.8 million in stock

Magnetar Financial LLC, a 10% owner of CoreWeave Inc. (CRWV), sold approximately $213.8 million worth of Class A Common Stock on August 13, 2026. This sale occurred as CoreWeave's stock has shown significant gains, with the company valued at $58.6 billion despite facing financial …

CoreWeave Stock Tumbles 12% — Analyst Flags Execution Risks Ahead Of Earnings

SILKWAVE INC Company Profile & Introduction

A Look at Aveanna Healthcare Holdings Inc (AVAH) After 9.2% Gain -- GF Value $5.20 vs Price $12.32

Aveanna Healthcare Holdings Inc (AVAH) recently saw a 9.2% stock gain, pushing its price to $12.32. However, GuruFocus estimates its intrinsic value (GF Value™) at $5.20, indicating significant overvaluation. The stock has an "Above Average" GF Score™ of 63/100, but is flagged for weak …

TerraVest Industries (TSX:TVK) Profit Surge Runs Into Margin Pressure

Applied Digital (APLD) Stock Trades Up, Here Is Why

What Happened? Shares of digital infrastructure provider Applied Digital (NASDAQ:APLD) jumped 5.4% in the afternoon session after the company reported strong earnings reports from several AI infrastructure peers signaled robust industry-wide demand. The rally was part of a broader upswing for 'neocloud' stocks, following …

CoreWeave COO Sachin Jain sells $110 in company stock

CoreWeave COO Sachin Jain sold 1 share of Class A Common Stock for $110 on August 12, 2026, as part of a pre-planned trading strategy. This sale leaves him with 147,784 shares, while the company's stock has seen a significant year-to-date increase. Several analysts …

Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?

Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short …

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

3 Reasons to Avoid GBTG and 1 Stock to Buy Instead

3 Reasons to Avoid GBTG and 1 Stock to Buy Instead What a time it's been for American Express Global Business Travel. In the past six months alone, the company's stock price has increased by a massive 76.8%, reaching $9.44 per share. This was …

Flight Centre Stock And Other Founder Led Picks Worth A Closer Look

Sorpresa en Wall Street: CoreWeave saltó 20% tras presentar sus resultados

D-Wave Quantum (NASDAQ:QBTS) Shares Up 1.3% - What's Next?

VisionWave Holdings (VWAV) terminates 51% Meteor Aerospace acquisition valued at $40M

VisionWave Holdings (VWAV) has terminated its binding agreement to acquire a 51% stake in Meteor Aerospace Ltd., an acquisition valued at $40 million. The decision came after VisionWave completed its due diligence review. The company confirmed that no shares were issued, no consideration was …

VisionWave Holdings ends acquisition agreement with Meteor Aerospace

VisionWave Holdings Inc. (NASDAQ:VWAV) announced the termination of its agreement to acquire a majority stake in Meteor Aerospace Ltd. The decision followed a due diligence review, and no shares were issued nor were any early termination penalties incurred. This comes after previous news of …

LightWave Acquisition (LWAC) logs $3.4M income but flags going concern risk

LightWave Acquisition Corp. (LWAC), a Cayman Islands SPAC, reported a net income of $3.39 million for the first half of 2026, primarily from earnings on its Trust Account investments. Despite this income, the company flagged substantial doubt about its ability to continue as a …

Quantum Computing Earnings Offered a Reality Check. What Comes Next.

IonQ, Quantinuum, and other notable names in the quantum sector have reported earnings, which broadly showed that traction continues to grow. Continue Reading

Divisadero group (DAVE) discloses 6.1% beneficial stake in Dave Inc.

Divisadero Street Capital Management, LP and its related entities have disclosed a 6.1% beneficial ownership stake in Dave Inc. (DAVE), totaling 699,366 shares of Class A common stock. This passive investment is shared among the reporting persons, including William Zolezzi and various Divisadero Street …

VisionWave Holdings (NASDAQ: VWAV) flags steep Q2 loss and late 10-Q filing

Canadian Imperial Bank of Commerce Issues Positive Forecast for TerraVest Industries (TSE:TVK) Stock Price

Dave Inc. (DAVE) stake of 2.5% reported by G1 Execution and Susquehanna

G1 Execution Services, LLC and Susquehanna Securities, LLC have reported a combined beneficial ownership of 291,325 shares, or 2.5%, of Dave Inc.'s Class A Common Stock. This ownership is based on 11,441,201 shares outstanding as of June 30, 2026. The filing indicates that G1's …

Travere Therapeutics (TVTX) sees Armistice Capital report 1.67% ownership in 13G/A

Armistice Capital and Steven Boyd have filed an amended Schedule 13G disclosing a 1.67% beneficial ownership stake in Travere Therapeutics (TVTX). This ownership translates to 1,572,539 shares of common stock, with shared voting and dispositive power, falling below the 5% reporting threshold for a …

Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net Loss - Has The Bull Case Changed?

Travere Therapeutics reported strong Q2 2026 revenue of US$169.58 million, a significant increase from the previous year, but also a wider net loss of US$34.8 million. The article discusses how this revenue growth, driven by its drug FILSPARI, reinforces the company's investment narrative focused …